66909-29-3

Basic information

• Product Name: 6-Chloro-5-methylpyridine-3-carboxylic acid
• Synonyms: 6-Chloro-5-methylpyridine-3-carboxylic acid;6-Chloro-5-methylnicotinic acid;6-Chloro-5-methylpyridine-3-carboxylic acid, 5-Carboxy-2-chloro-3-methylpyridine;5-Carboxy-2-chloro-3-methylpyridine
• CAS NO: 66909-29-3
• Molecular Formula: C₇H₆ClNO₂
• Molecular Weight: 172
• Mol File: 66909-29-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 6-Chloro-5-methylpyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-5-methylpyridine-3-carboxylic acid(66909-29-3)
• EPA Substance Registry System: 6-Chloro-5-methylpyridine-3-carboxylic acid(66909-29-3)

Safety Data

• Hazardous Substances Data: 66909-29-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-5-methylpyridine-3-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its ability to be further functionalized and modified makes it a versatile building block for drug development.
Used in the Treatment of ROR-γ-Mediated Diseases:
6-Chloro-5-methylpyridine-3-carboxylic acid is used as a ROR-γ (Retinoic Acid Receptor-Related Orphan Receptor Gamma) inhibitor for the treatment of ROR-γ-mediated diseases. By targeting and inhibiting the ROR-γ receptor, this compound can potentially modulate immune responses and treat conditions such as autoimmune disorders, inflammatory diseases, and certain types of cancer.

Upstream product

• 176433-43-5 6-chloro-5-methylpyridine-3-carboxaldehyde 
• 59782-89-7 2-Chloro-5-iodo-3-methylpyridine 
• 124-38-9 carbon dioxide 
• 4403-61-6 2-methyl-2-butene nitrile 
• 30574-97-1 tiglonitrile 

Downstream Products

• 942511-70-8 6-chloro-5-methylnicotinic acid ethyl ester 
• 1122090-20-3 6-(Isopropylamino)-5-methylnicotinic acid 
• 1186617-39-9 5-methyl-6-pyrrolidin-1-yl-nicotinic acid 
• 1186618-27-8 C₂₄H₃₁N₅O₃ 
• 1186617-62-8 2-ethyl-6-methyl-4-[5-(5-methyl-6-pyrrolidin-1-yl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-phenol 
• 1186618-30-3 N-((S)-3-{2-ethyl-6-methyl-4-[5-(5-methyl-6-pyrrolidin-1-yl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]phenoxy}-2-hydroxypropyl)-2-hydroxyacetamide 
• 1186617-59-3 N-((S)-3-{4-[5-(6-diethylamino-5-methyl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}-2-hydroxypropyl)-2-hydroxyacetamide 
• 1516901-64-6 (S)-N-(3-(2-ethyl-4-(5-(6-isopropyl-5-methylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1122090-09-8 isopropyl 6-chloro-5-methylnicotinate 

Relevant articles and documents

First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump

Overexpression of efflux pumps is an important mechanism of bacterial resistance that results in the extrusion of antimicrobial agents outside the bacterial cell. Inhibition of such pumps appears to be a promising strategy that could restore the potency of existing antibiotics. The NorA efflux pump of Staphylococcus aureus confers resistance to a wide range of unrelated substrates, such as hydrophilic fluoroquinolones, leading to a multidrug-resistance phenotype. In this work, approximately 150 heterocyclic boronic species were evaluated for their activity against susceptible and resistant strains of S. aureus. Twenty-four hit compounds, although inactive when tested alone, were found to potentiate ciprofloxacin activity by a 4-fold increase at concentrations ranging from 0.5 to 8 μg/mL against S. aureus 1199B, which overexpresses NorA. Boron-free analogues showed no biological activity, thus revealing that the boron atom is crucial for biological activity. This work describes the first reported efflux pump inhibitory activity of boronic acid derivatives.

Novel S1P1 receptor agonists - Part 3: From thiophenes to pyridines

In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P 1 agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P1 agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P 1 agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P1 and S1P3 receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R1 are as described in the description, and salts thereof, and their use as orexin receptor antagonists.

Pyridin-3-yl derivatives as immunomodulating agents

The invention relates to pyridin-3-yl derivatives of Formula (I) wherein R1, R2, R3, R4, R5; R6 and A are as described in the description, their preparation and their use as pharmaceuticall

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula I.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituants are as defined in the claims.

PYRIDINE COMPOUNDS

The invention relates to pyridine compounds, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS

The invention relates to pyridin-3-yl derivatives of Formula (I) wherein R1, R2, R3, R4, R5; R6 and A are as described in the description, their preparation and their use as pharmaceuticall